Free Trial

Galectin Therapeutics (GALT) 10K Form and Latest SEC Filings 2026

Galectin Therapeutics logo
$2.25 +0.02 (+0.90%)
As of 05/6/2026 04:00 PM Eastern

Latest Galectin Therapeutics SEC Filings & Recent Activity

Galectin Therapeutics (NASDAQ:GALT) has submitted 489+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form EFFECT submitted on April 12, 2026.

Form 4
GALECTIN THERAPEUTICS INC Reports Ownership Change on Mar. 17, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Galectin Therapeutics Files Current Report on Mar. 31, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-K
Galectin Therapeutics Files Annual Report on Mar. 31, 2026

The 10-K contains Galectin Therapeutics's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

Galectin Therapeutics SEC Filing History

Browse Galectin Therapeutics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
04/12/2026 11:15 PM
Galectin Therapeutics (1133416) Filer
Form EFFECT
03/31/2026 3:11 PM
Galectin Therapeutics (1133416) Filer
Form S-3
Registration statement under Securities Act of 1933  
03/31/2026 6:50 AM
Galectin Therapeutics (1133416) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/31/2026 6:55 AM
Galectin Therapeutics (1133416) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/17/2026 8:46 AM
Brem Henry (1387877) Reporting
Galectin Therapeutics (1133416) Issuer
Form 3
Initial statement of beneficial ownership of securities  
03/17/2026 8:46 AM
Brem Henry (1387877) Reporting
Galectin Therapeutics (1133416) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/17/2026 6:50 AM
Galectin Therapeutics (1133416) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/22/2026 1:11 PM
Galectin Therapeutics (1133416) Issuer
LEWIS JOEL (1725595) Reporting
Form 4/A
01/21/2026 4:01 PM
Galectin Therapeutics (1133416) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/21/2026 4:03 PM
CARSON BENJAMIN SR (17940) Reporting
Galectin Therapeutics (1133416) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/21/2026 3:44 PM
Galectin Therapeutics (1133416) Issuer
Uihlein Richard E (1694903) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/21/2026 3:44 PM
Galectin Therapeutics (1133416) Issuer
Schwartz Elissa J. (1827177) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/21/2026 3:45 PM
AMELIO GILBERT F (1183247) Reporting
Galectin Therapeutics (1133416) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/21/2026 3:46 PM
Galectin Therapeutics (1133416) Issuer
OMENN GILBERT S (1184227) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/21/2026 3:46 PM
Galectin Therapeutics (1133416) Issuer
Shlevin Harold H. (1557082) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/21/2026 3:47 PM
CALLICUTT JACK W (1266773) Reporting
Galectin Therapeutics (1133416) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/21/2026 3:48 PM
Galectin Therapeutics (1133416) Issuer
LEWIS JOEL (1725595) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/21/2026 3:49 PM
ELDRED KARY (1543425) Reporting
Galectin Therapeutics (1133416) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/21/2026 3:49 PM
FREEMAN KEVIN D (1522478) Reporting
Galectin Therapeutics (1133416) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/21/2026 3:50 PM
Galectin Therapeutics (1133416) Issuer
Jamil Khurram (2032345) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/21/2026 3:50 PM
Galectin Therapeutics (1133416) Issuer
Zordani Richard A. Jr. (1827180) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/13/2026 7:40 AM
Galectin Therapeutics (1133416) Issuer
LEWIS JOEL (1725595) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/12/2026 4:00 PM
Galectin Therapeutics (1133416) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/06/2026 3:53 PM
Galectin Therapeutics (1133416) Issuer
Jamil Khurram (2032345) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/06/2026 3:54 PM
CALLICUTT JACK W (1266773) Reporting
Galectin Therapeutics (1133416) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/06/2026 3:54 PM
Galectin Therapeutics (1133416) Issuer
LEWIS JOEL (1725595) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/06/2026 10:10 AM
Galectin Therapeutics (1133416) Subject
Shlevin Harold H. (1557082) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/05/2026 3:07 PM
Galectin Therapeutics (1133416) Issuer
Jamil Khurram (2032345) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/02/2026 3:56 PM
CALLICUTT JACK W (1266773) Reporting
Galectin Therapeutics (1133416) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/02/2026 3:57 PM
Galectin Therapeutics (1133416) Subject
Jamil Khurram (2032345) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/02/2026 3:58 PM
Galectin Therapeutics (1133416) Subject
LEWIS JOEL (1725595) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/31/2025 3:08 PM
Galectin Therapeutics (1133416) Subject
Jamil Khurram (2032345) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/23/2025 12:17 PM
ELDRED KARY (1543425) Reporting
Galectin Therapeutics (1133416) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2025 12:19 PM
FREEMAN KEVIN D (1522478) Reporting
Galectin Therapeutics (1133416) Issuer
Form 4/A
12/23/2025 12:21 PM
FREEMAN KEVIN D (1522478) Reporting
Galectin Therapeutics (1133416) Issuer
Form 4/A
12/23/2025 10:28 AM
ELDRED KARY (1543425) Reporting
Galectin Therapeutics (1133416) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2025 10:29 AM
FREEMAN KEVIN D (1522478) Reporting
Galectin Therapeutics (1133416) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/19/2025 3:05 PM
Galectin Therapeutics (1133416) Issuer
Shlevin Harold H. (1557082) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/19/2025 3:06 PM
Galectin Therapeutics (1133416) Issuer
Jamil Khurram (2032345) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/19/2025 3:08 PM
Galectin Therapeutics (1133416) Issuer
LEWIS JOEL (1725595) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/19/2025 6:55 AM
Galectin Therapeutics (1133416) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/18/2025 9:34 AM
10X Capital Management, LLC (1457247) Reporting
10X Fund, L.P. (1453356) Reporting
CZIRR JAMES C (1260641) Reporting
Galectin Therapeutics (1133416) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/17/2025 3:44 PM
Galectin Therapeutics (1133416) Subject
Shlevin Harold H. (1557082) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/17/2025 3:33 PM
Galectin Therapeutics (1133416) Subject
Jamil Khurram (2032345) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/16/2025 3:22 PM
Galectin Therapeutics (1133416) Issuer
Shlevin Harold H. (1557082) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/15/2025 3:32 PM
Galectin Therapeutics (1133416) Subject
Shlevin Harold H. (1557082) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/15/2025 3:45 PM
Galectin Therapeutics (1133416) Subject
Shlevin Harold H. (1557082) Reporting
Form 144/A
12/12/2025 4:27 PM
Galectin Therapeutics (1133416) Subject
Shlevin Harold H. (1557082) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/10/2025 7:15 AM
Galectin Therapeutics (1133416) Issuer
Shlevin Harold H. (1557082) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/09/2025 3:36 PM
Galectin Therapeutics (1133416) Subject
Shlevin Harold H. (1557082) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/08/2025 6:40 PM
Galectin Therapeutics (1133416) Subject
Shlevin Harold H. (1557082) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
12/08/2025 12:21 PM
10X Capital Management, LLC (1457247) Reporting
10X Fund, L.P. (1453356) Reporting
CZIRR JAMES C (1260641) Reporting
Galectin Therapeutics (1133416) Issuer
Form 4/A
12/08/2025 7:00 AM
Galectin Therapeutics (1133416) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/03/2025 11:00 AM
Galectin Therapeutics (1133416) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/19/2025 3:01 PM
CALLICUTT JACK W (1266773) Reporting
Galectin Therapeutics (1133416) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/19/2025 3:01 PM
Galectin Therapeutics (1133416) Issuer
LEWIS JOEL (1725595) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/14/2025 6:50 AM
Galectin Therapeutics (1133416) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/14/2025 6:55 AM
Galectin Therapeutics (1133416) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/13/2025 4:03 PM
Galectin Therapeutics (1133416) Subject
Jamil Khurram (2032345) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/10/2025 6:56 AM
Galectin Therapeutics (1133416) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/24/2025 7:18 PM
10X Capital Management, LLC (1457247) Reporting
10X Fund, L.P. (1453356) Reporting
CZIRR JAMES C (1260641) Reporting
Galectin Therapeutics (1133416) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/22/2025 7:00 AM
Galectin Therapeutics (1133416) Filer
Form DEF 14A
10/22/2025 7:00 AM
Galectin Therapeutics (1133416) Filer
Form DEFA14A
10/22/2025 7:01 AM
Galectin Therapeutics (1133416) Filer
Form ARS
10/10/2025 5:27 PM
10X Capital Management, LLC (1457247) Reporting
10X Fund, L.P. (1453356) Reporting
Galectin Therapeutics (1133416) Issuer
Form 5
Annual statement of changes in beneficial ownership of securities  
09/15/2025 11:45 AM
Galectin Therapeutics (1133416) Issuer
LEWIS JOEL (1725595) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/15/2025 11:45 AM
CALLICUTT JACK W (1266773) Reporting
Galectin Therapeutics (1133416) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/12/2025 3:38 PM
Galectin Therapeutics (1133416) Subject
LEWIS JOEL (1725595) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/12/2025 3:37 PM
CALLICUTT JACK W (1266773) Reporting
Galectin Therapeutics (1133416) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/08/2025 6:56 AM
Galectin Therapeutics (1133416) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/14/2025 6:53 AM
Galectin Therapeutics (1133416) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/14/2025 6:55 AM
Galectin Therapeutics (1133416) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/22/2025 6:36 AM
ELDRED KARY (1543425) Reporting
Galectin Therapeutics (1133416) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/18/2025 9:38 AM
FREEMAN KEVIN D (1522478) Reporting
Galectin Therapeutics (1133416) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/09/2025 6:55 AM
Galectin Therapeutics (1133416) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/16/2025 11:01 AM
Galectin Therapeutics (1133416) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/11/2025 5:25 PM
CZIRR JAMES C (1260641) Reporting
Galectin Therapeutics (1133416) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
06/11/2025 4:18 PM
CZIRR JAMES C (1260641) Reporting
Galectin Therapeutics (1133416) Issuer
Form 5
Annual statement of changes in beneficial ownership of securities  
05/15/2025 6:50 AM
Galectin Therapeutics (1133416) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/15/2025 6:55 AM
Galectin Therapeutics (1133416) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/12/2025 6:55 AM
Galectin Therapeutics (1133416) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)

Galectin Therapeutics SEC Filings - Frequently Asked Questions

Galectin Therapeutics (GALT) has submitted 489+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

Galectin Therapeutics's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results.

The most recent filing was a Form EFFECT submitted on April 12, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:GALT) was last updated on 5/7/2026 by MarketBeat.com Staff.
From Our Partners